Ignite Creation Date:
2024-05-06 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05808634
Status:
RECRUITING
Last Update Posted:
2023-04-11
First Post:
2023-03-17
Brief Title:
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma
Sponsor:
BioAtla Inc
Organization:
BioAtla Inc
Study Overview
Official Title:
An Open-label Multicenter Phase 1 Study Evaluating the Safety Pharmacokinetics and Efficacy of BA3182 a Bispecific Epithelial Cell Adhesion Molecule EpCAMCD3 Antibody in Patients With Advanced Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Detailed Description:
This is a multi-center open-label Phase 1 study designed to evaluate the safety tolerability PK immunogenicity and antitumor activity of BA3182 in patients with advanced adenocarcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None